Login
$FHTX
$2.05 +$0.00 (0.0%) Close

Company Executives

$FHTX Management Team

Mr. Carlos Costa

Chief People Officer

Age 52
Compensation -
Sex Male

Dr. Alfonso Quints-Cardama

Chief Medical Officer

Age 54
Compensation $1.845M USD
Sex Male

Ms. Karin Hellsvik

IR Contact Officer

Age -
Compensation -
Sex Female

Mr. Adrian Gottschalk

President

Chief Executive Officer

Director

Age 49
Compensation $1.560M USD
Sex Male

Mr. Steven Bellon

Chief Scientific Officer

Age 60
Compensation $1.187M USD
Sex Male

Mr. Michael LaCascia

Chief Legal Officer

Age 61
Compensation $1.988M USD
Sex Male

Dr. Anna Rivkin

Chief Business Officer

Age 51
Compensation $1.473M USD
Sex Female

Mr. Ryan Maynard

Chief Financial Officer

Age 56
Compensation -
Sex Male
Directors
10
serving now
Independent
0 of 1
stated in the proxy; 9 not stated
Average tenure
8.0 years
from year joined
CEO also chairs the board
Not stated
no chair stated
Director Age On board Independent Committees Other public boards 2025 pay Source
Adrian Gottschalk
Not stated Not stated Not independent None stated None stated Paid as CEO
Douglas Cole
65 2015
11 years
Not stated
Compensation Committee
None stated $177,321
Balkrishan (Simba) Gill
62 2017
9 years
Not stated None stated None stated Not stated
B. Lynne Parshall
72 2022
4 years
Not stated None stated Cytokinetics, Inc. $151,754
Scott Biller
Not stated Not stated Not stated None stated None stated Not stated
Stuart Duty
Not stated Not stated Not stated
Audit Committee
None stated $194,669
Neil J. Gallagher
Not stated Not stated Not stated None stated None stated Not stated
Thomas J. Lynch, Jr.
Not stated Not stated Not stated None stated None stated $140,087
Michael Mendelsohn
Not stated Not stated Not stated None stated None stated $147,321
Ian F. Smith
Not stated Not stated Not stated None stated None stated $131,970

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

8 disclosed in the proxy filed Apr 30, 2026
Cigall Kadoch, Ph.D.
academic co-founder, former director and holder of more than 5% of our Common Stock
Amount not stated

Consulting agreement for advisory services on chromatin remodeling products, with a share grant and consulting fee.

Cigall Kadoch, Ph.D.
academic co-founder, former director and holder of more than 5% of our Common Stock
$0.2 million
2025 and 2024

Payments to Dr. Kadoch under the consulting agreement.

Eli Lilly and Company
5% or greater shareholder in the Company
Amount not stated

Strategic collaboration under the Lilly Collaboration Agreement, with a stock purchase of 4,000,000 shares at $20.00 per share and shared program costs.

Eli Lilly and Company
5% or greater shareholder in the Company
$8.2 million
2025

Payments by the Company to Lilly for 2025 under the collaboration.

BVF Partners, L.P.
holder of more than 5% of our common stock
Approximately $25 million
2026

Purchase of common stock and pre-funded warrants in the January 2026 equity offering.

Flagship Pioneering, Inc.
holder of more than 5% of our common stock
Approximately $15 million
2026

Purchase of pre-funded warrants in the January 2026 equity offering.

Deerfield Partners LP
holder of more than 5% of our common stock
Approximately $5 million
2026

Purchase of common stock in the January 2026 equity offering.

FMR LLC
holder of more than 5% of our common stock
$5 million
2026

Purchase of common stock in the January 2026 equity offering.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support